RecruitingPhase 2NCT06721871
Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)
Studying Intractable diarrhea of infancy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Napo Pharmaceuticals, Inc.
- Principal Investigator
- Lissette Jimenez, MD, MPHBoston Children's Hospital
- Intervention
- Crofelemer Powder for Oral Solution(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2025 – 2026
Study locations (3)
- Boston Children's Hospital, Boston, Massachusetts, United States
- UOS Gastroenterolgia e Riabilitazione nutrizionale Piazza Sant' Onofrio 4, Rome, Italy
- Al Jalila Children's Hospital, Dubai, United Arab Emirates
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06721871 on ClinicalTrials.gov